Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06844474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

StatusRecruiting
PhasePhase 2
Started2025-03-07
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Aug 31, 2026 → Dec 2026
See other at-risk trials from Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Amendment history

2026-09-02
Study Status v2
Primary completion pushed: 2026-08-31 → 2026-12
Completion pushed: 2028-02-29 → 2028-12
2025-03-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-03-31→confirmed 2025-03-07
Study sitesdetails revised at 1 of 1 site
2025-02-19
Original filing
This study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.
Trial Details
NCT Number NCT06844474
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions NSCLC
Enrollment 300 participants
Start Date 2025-03-07
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-08